FindTrial
Sign In

JNJ-73763989

DRUG14 trials

Sponsors

Janssen - Cilag International, Janssen Sciences Ireland UC, Janssen Research & Development, LLC

Conditions

HealthyHepatic ImpairmentHepatitis BHepatitis B and Hepatitis D Viral Co-infectionHepatitis B, ChronicHepatitis D, ChronicRenal Impairment

Phase 1

A Study of JNJ-73763989 in Healthy Japanese Adult Participants
CompletedNCT04002752
Janssen Sciences Ireland UCHealthy
Start: 2019-07-04End: 2019-08-23Updated: 2025-02-03
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989
CompletedNCT04208386
Janssen Sciences Ireland UCHepatic Impairment
Start: 2020-01-08End: 2020-07-20Updated: 2020-09-30
A Study of JNJ-73763989 in Healthy Chinese Adult Participants
CompletedNCT04586439
Janssen Research & Development, LLCHealthy
Start: 2020-11-24End: 2021-02-18Updated: 2021-03-08
A Study of JNJ-73763989 in Adult Participants With Renal Impairment
CompletedNCT04963738
Janssen Research & Development, LLCRenal Impairment
Start: 2021-09-22End: 2022-10-17Updated: 2023-11-09
A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection
CompletedNCT05123599
Janssen Research & Development, LLCHepatitis B, Chronic
Start: 2021-12-06End: 2024-06-26Updated: 2025-05-26

Phase 2

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
CompletedNCT03982186
Janssen Sciences Ireland UCHepatitis B, Chronic
Start: 2019-08-01End: 2022-04-26Updated: 2025-02-04
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
CompletedNCT04129554
Janssen Sciences Ireland UCHepatitis B, Chronic
Start: 2019-11-06End: 2022-06-09Updated: 2025-02-04
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
CompletedNCT04439539
Janssen Research & Development, LLCHepatitis B, Chronic
Start: 2020-09-14End: 2024-02-13Updated: 2025-06-24
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
CompletedNCT04535544
Janssen Research & Development, LLCHepatitis D, Chronic
Start: 2020-09-17End: 2025-03-05Updated: 2025-04-25
A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
CompletedNCT04585789
Janssen Research & Development, LLCHepatitis B
Start: 2021-03-11End: 2024-01-09Updated: 2025-05-21
A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
CompletedNCT04667104
Janssen Research & Development, LLCHepatitis B, Chronic
Start: 2021-02-01End: 2023-04-17Updated: 2024-07-03
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection
TerminatedNCT05005507
Janssen Research & Development, LLCHepatitis B, Chronic
Start: 2021-11-03End: 2021-12-29Updated: 2024-03-06
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
CompletedNCT05275023
Janssen Research & Development, LLCHepatitis B, Chronic
Start: 2022-06-30End: 2024-05-31Updated: 2025-04-25
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus
CompletedCTIS2023-506763-33-00
Janssen - Cilag InternationalHepatitis B and Hepatitis D Viral Co-infection
Start: 2020-12-18End: 2025-01-15Target: 14Updated: 2024-09-02

Related Papers

Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study.
2025-11-04
Viral sequence analysis of chronic hepatitis B patients treated with the siRNA JNJ-73763989 in phase II clinical trials.
2025-10-09
Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study.
2025-07-09
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B.
2025-02-261 citations
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2
Journal of Hepatology2024-04-0534 citations
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
2023-07-1055 citations
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B
Antiviral Therapy2022-06-0116 citations